Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France

Anne Bénard-Laribière,1 Antoine Pariente,1,2 Elodie Pambrun,1 Bernard Bégaud,1,2 Laurence Fardet,3,4 Pernelle Noize1,2,5

ABSTRACT

Objectives To study trends in use of oral glucocorticoids (GCs) among adults, characteristics of oral GC initiators and prescriptions for the prevention of potential adverse effects associated with GC therapy.

Design First, a cross-sectional study repeated yearly was performed from 2007 to 2014 in a nationwide representative sample. Second, characteristics of initiators and patterns of GC therapy during the year following treatment initiation were described in a cohort of patients who began GC between 2007 and 2013.

Setting Population-based study using data from the French reimbursement healthcare system (covering approximately 90% of the population) in patients aged ≥18 years.

Results Over the study period, the prevalence of oral GC use ranged from 14.7% to 17.1% (95% CI 17.0%–17.2%) with a significant increase of 14.1% (95% CI +13.5% to +14.8%). The 2007–2013 cohort of oral GC initiators comprised 206759 individuals. Oral GC use was mostly short-term (68% of unique reimbursement) and more than half of short-term users took concurrent antibiotics or respiratory/otological drugs. Chronic users (≥6 reimbursements/year) represented 1.8% (n=3789) of the cohort. The proportion of chronic users with comorbidities likely to be worsened by GC use (diabetes, psychotic disorders, osteoporosis) was 25%. Among patients at increased risk of osteoporosis, 62% received specific prevention/monitoring measures and only 27% had a bisphosphonate. Half of chronic oral GC users had a concurrent reimbursement of a proton pump inhibitor in the absence of non-steroidal anti-inflammatory drug use.

Conclusions Oral GC use was highly widespread and increased among adults from 2007 to 2014. The overwhelming short-term use could mainly concern a growing use of unjustified prescriptions rather than situations with a favourable benefit/risk ratio. For chronic users, our findings plead for the development of interventions designed to improve monitoring with regard to the frequent comorbidities at risk and inappropriate prescribing of preventive therapeutic measures.

INTRODUCTION

Oral glucocorticoids (GCs) have been used for more than 60 years for their substantial anti-inflammatory and immunosuppressive effects in several acute and chronic disorders, both for reducing disease activity and pain.1 However, their use is limited by the occurrence of adverse reactions related to their pharmacological properties that are mainly to be feared with higher dosages or long-term use. These associated risks include infections, osteoporosis and fractures, hyperglycaemia, neuropsychiatric disorders and muscle atrophy. Recommendations on the management of GC therapy based on expert consensus are available for the prevention of GC-induced osteoporosis2,3; regarding other significant adverse reactions, advice on pretreatment and treatment monitoring have been issued4,5 but no consensual recommendations exist.

Besides these well-known adverse consequences, the relevance of some other potential adverse reactions is debated, such as the impact on electrolyte homeostasis due to mineralocorticoid effects or the risk of peptic ulcer. While potassium loss seems negligible in practice,7 some physicians persist in prescribing potassium supplementation, which in some situations may carry a risk of marked hyperkalaemia.8 Similarly, despite the literature suggesting no benefit from proton pump
inhibitors (PPIs) prophylaxis in patients taking systemic GCs without concomitant non-steroidal anti-inflammatory drug (NSAID) use, many prescribers still consider GCs as a cause of upper gastrointestinal complications and systematically add PPIs to their prescriptions.

Few studies have reported the use of oral GCs in the general population, and short-term use has rarely been quantified as it is considered safe. This population-based study aimed at describing trends in the use of oral GCs among adults, the characteristics of GC initiators and the prescriptions for the prevention of potential adverse effects associated with GC therapy.

METHODS
Data source
The study was conducted using the French reimbursement database (Echantillon Généraliste de Bénéficiaires, EGB). The EGB is a representative sample of the population covered by the national healthcare insurance system (approximately 90% of the whole population, irrespective of socioeconomic status) obtained by 1/97th random sampling with stratification on sex and age. For all beneficiaries, it consists of the exhaustive recording of drug reimbursements, with identification of medication packs, including the number and dosage strengths of treatment units. The database also contains hospitalisation data (diagnoses and dates) and the existence of certain chronic diseases (Affections de Longue Durée, ALD, an administrative status allowing full reimbursement of healthcare for a given condition, eg, diabetes, cancer, psychosis). Diagnoses or indications for prescribing are not collected in the EGB database, nor the dose prescribed or the duration of treatment. Details on the EGB database have been described elsewhere.

Study design
Cross-sectional study
In order to study temporal trends in the use of GCs, a cross-sectional study was repeated yearly among the population aged ≥18 years from 1 January 2007 to 31 December 2014. All individuals who had at least one reimbursement of an oral GC (ie, betamethasone, dexamethasone, methylprednisolone, prednisolone and prednisone) were identified for each year studied.

Cohort study
To study characteristics of GC users and therapeutic behaviour associated with the prescription, a cohort of oral GC initiators was identified. GC initiators were defined as an incident reimbursement of oral GC between 1 January 2007 and 31 December 2013, without any in the preceding year. This definition was retained to ensure incident use was identified in a conservative manner even if other definitions can be found in the literature (eg, prescription-free, 90-day or 6-month period). The index date was the date the incident GC was reimbursed. Each GC initiator was followed until 1 year since index date, the date of death or the end of data availability in the database, whichever came first. Identified individuals could only contribute once to the cohort constitution.

Characteristics of GC initiators
GC initiators were described in terms of age and sex at index date. Comorbidities that may represent situations at risk in the event of GC use (ie, diabetes, psychotic disorders and osteoporosis) were described, as were chronic disorders constituting recognised indications for GC therapy: rheumatic diseases (eg, rheumatoid arthritis, polymyalgia rheumatica/giant cell arteritis, lupus and vasculitis), obstructive pulmonary diseases (ie, asthma, chronic obstructive pulmonary disease and chronic respiratory failure), inflammatory bowel diseases (ie, Crohn’s disease and ulcerative colitis) and multiple sclerosis. Comorbidities and indications for oral GC treatment were identified using data from diagnoses related to hospital stays or chronic diseases (ALDs) and medication reimbursement data in the 12-month period preceding the patient’s index date. A description of drugs reimbursed at index date (concurrent drugs) was also performed as these potentially reflect the indication of GC therapy.

Therapeutic behaviour associated with the prescription of GCs
Over the year following GC treatment initiation, we scrutinised two types of preventive measures: (1) those that should be systematically considered, such as prevention/monitoring of osteoporosis among individuals at increased risk of osteoporosis; and (2) those for whom no consensus exists and/or that might be inappropriate (potassium supplementation without serum potassium assay, and PPI prophylaxis without concurrent NSAID or aspirin use).

To assess the prevention and monitoring of osteoporosis, individuals at increased risk of GC-induced osteoporosis were defined as those who had at least six reimbursements of GCs during the 12-month period following the index date and (1) were aged 70 years and older or (2) had a history of untreated osteoporosis during the 12 months preceding the index date. Measures for prevention/monitoring of osteoporosis among these individuals were identified by at least one of the following criteria: (1) bone mineral density measurement (at least one reimbursement for dual-energy X-ray absorptiometry, DXA) or (2) prescription of drugs indicated for osteoporosis management (at least one reimbursement for calcium, vitamin D, bisphosphonates, denosumab, raloxifene, teriparatide, strontium ranelate and calcitonin). For non-consensually recommended measures, potentially inappropriate potassium supplementation was defined as at least one concurrent reimbursement of oral GC and potassium supplements without any serum potassium assay during the two preceding weeks. A priori non-indicated prescription of PPIs was defined as at least one concurrent reimbursement of oral GC and PPI in the absence of NSAID or aspirin on the same date.
Trends in use of oral GCs

The annual prevalence of GC use was defined as the proportion of GC users per 100 individuals for the corresponding year. It was first calculated for GCs overall and then by considering each GC individually. All prevalence estimates were further stratified according to the number of GCs reimbursed per year (1, 2–5, ≥6) and by sex and age (five categories according to age on 1 January in each year: 18–49 years, 50–59 years, 60–69 years, 70–79 years and ≥80 years), and were quantified together with their two-sided 95% CIs. To study trends in prevalent use over the study period, relative changes in prevalence of use were estimated by using the year 2007 as reference. Relative change estimates, quantified together with their two-sided 95% CIs, were calculated using the percentiles bootstrap method.

Characteristics of GC initiators and therapeutic behaviour associated with prescription of GCs

All parameters were examined overall and stratified according to the duration of therapy. The EGB database does not provide the total duration of treatments, but GC treatment is issued for a maximum of 30 days in France and individuals have to renew their treatment each month. We consequently assessed GC treatment duration according to the number of oral GC reimbursements (consecutive or not) identified during the 12-month period following the index date. Users who had a unique reimbursement were arbitrarily defined as short-term users, those who had 2–5 reimbursements as mid-term users and those with ≥6 reimbursements as long-term users. We assumed that individuals with ≥6 reimbursements/year were treated for chronic diseases. Measures for the prevention of osteoporosis were examined only for individuals with an increased risk of osteoporosis as defined above.

All analyses were performed using SAS V.9.4 software. All codes used for the identification of the studied comorbidities and medications are listed in online supplementary tables 1–5.

RESULTS

Trends in use of oral GCs from 2007 to 2014

Of the 382572 individuals included in the study in 2007, 56126 had at least one reimbursement of an oral GC: the prevalence of GC use was 14.7% (95% CI 14.6% to 14.8%) in 2007. It was 17.1% (95% CI 17.0% to 17.2%) in 2014, corresponding to a 14.1% increase (95% CI +13.5% to +14.8%) compared with 2007 (figure 1). This rise was more pronounced in individuals aged 50–59 years (+18.4% (95% CI +17.0% to +20.0%)) and 60–69 years (+19.7% (95% CI +17.9% to +21.5%)). It mostly concerned prednisolone (+21.6% (95% CI +20.8% to +22.3%)) (see online supplementary figure S1); this was the most used GC over the study period, irrespective of age and sex.

The prevalence of use was higher among women whatever their age, the highest value being observed in those aged 50–59 years (21.9% in 2014 (95% CI 21.4% to 22.3%)) (see online supplementary figure S2). Concerning the number of GCs reimbursed per year, the prevalence of unique reimbursements slightly increased from 10.3% in 2007 to 11.8% in 2014 (+12.7% (95% CI +11.8% to +13.5%)). The proportion of individuals who had 2–5 reimbursements per year rose from 3.8% to 4.6% (+18.6% (95% CI +17.4% to +19.9%)). Conversely, the percentage of individuals with ≥6 reimbursements per year remained stable and ranged between 0.6% and 0.7% (+7.9% increase (95% CI +3.8% to +11.8%) compared with 2007).

Characteristics of GC initiators

The 2007–2013 cohort of GC initiators comprised 206759 individuals: 58.0% were women and the median age was 45 years (IQR: 32–59). More than two-thirds of initiators (67.6%) had a unique reimbursement of GC over the year following treatment initiation (short-term users). Midterm users represented 30.6% of the study cohort and long-term users 1.8%. Compared with short-term and mid-term users, long-term users were more likely to be older (median age: 63 years, IQR: 49–76); one-quarter (24.5%) had at least one comorbidity at treatment initiation that was likely to increase the risk of adverse drug reaction in the event of GC treatment.

Figure 1 Trends in prevalence of oral glucocorticoid use in France per year from 2007 to 2014. Prevalence estimates with 95% CIs (error bars) (A) overall and by sex, and (B) by age.
Table 1  Characteristics of oral glucocorticoid (GC) initiators, overall and according to the number of oral GC reimbursements over the year following treatment initiation (figures are percentages)

<table>
<thead>
<tr>
<th></th>
<th>All GC initiators</th>
<th>Short-term users*</th>
<th>Mid-term users*</th>
<th>Long-term users*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>206759</td>
<td>139703</td>
<td>63267</td>
<td>3789</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Men</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age groups (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–49</td>
<td>58.8</td>
<td>60.0</td>
<td>58.2</td>
<td>25.5</td>
</tr>
<tr>
<td>50–59</td>
<td>16.6</td>
<td>16.3</td>
<td>17.2</td>
<td>16.9</td>
</tr>
<tr>
<td>60–69</td>
<td>12.0</td>
<td>11.6</td>
<td>12.3</td>
<td>18.9</td>
</tr>
<tr>
<td>70–79</td>
<td>7.8</td>
<td>7.4</td>
<td>7.7</td>
<td>22.0</td>
</tr>
<tr>
<td>≥80</td>
<td>4.9</td>
<td>4.8</td>
<td>4.6</td>
<td>16.7</td>
</tr>
<tr>
<td>Mean number of reimbursements/year (±SD)</td>
<td>1.6 (±1.4)</td>
<td>1*</td>
<td>2.5 (±0.8)</td>
<td>9.2 (±3.1)</td>
</tr>
<tr>
<td>Comorbidities at risk for GC users†</td>
<td>10.6</td>
<td>10.0</td>
<td>10.9</td>
<td>24.5</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5.3</td>
<td>5.2</td>
<td>5.1</td>
<td>12.1</td>
</tr>
<tr>
<td>Psychotic disorders</td>
<td>2.6</td>
<td>2.5</td>
<td>2.9</td>
<td>3.6</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>3.3</td>
<td>3.0</td>
<td>3.6</td>
<td>11.0</td>
</tr>
<tr>
<td>Identified GC recognised indications†</td>
<td>27.3</td>
<td>23.7</td>
<td>33.4</td>
<td>61.1</td>
</tr>
<tr>
<td>Obstructive pulmonary diseases</td>
<td>21.3</td>
<td>19.1</td>
<td>26.0</td>
<td>26.2</td>
</tr>
<tr>
<td>Cancer</td>
<td>6.4</td>
<td>4.9</td>
<td>8.2</td>
<td>31.9</td>
</tr>
<tr>
<td>Rheumatic diseases</td>
<td>1.0</td>
<td>0.6</td>
<td>1.1</td>
<td>12.1</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>0.4</td>
<td>0.2</td>
<td>0.5</td>
<td>5.7</td>
</tr>
<tr>
<td>Polymyalgia rheumatica/giant cell arteritis</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>3.9</td>
</tr>
<tr>
<td>Inflammatory bowel diseases</td>
<td>0.6</td>
<td>0.4</td>
<td>0.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Concurrent drugs at index date</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td>59.1</td>
<td>60.6</td>
<td>57.7</td>
<td>23.9</td>
</tr>
<tr>
<td>Respiratory/otological drugs‡</td>
<td>50.1</td>
<td>51.1</td>
<td>49.9</td>
<td>16.7</td>
</tr>
<tr>
<td>Concurrent antibiotics and respiratory/otological drugs</td>
<td>31.8</td>
<td>32.3</td>
<td>32.2</td>
<td>8.9</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td>6.5</td>
<td>6.4</td>
<td>6.9</td>
<td>7.2</td>
</tr>
<tr>
<td>Analgesics</td>
<td>46.0</td>
<td>46.5</td>
<td>45.6</td>
<td>34.6</td>
</tr>
</tbody>
</table>

* Short-term users: one reimbursement/year; mid-term users: 2–5 reimbursements/year; long-term users: ≥6 reimbursements.
† At least one comorbidity or indication.
‡ Nasal and throat preparations, antihistamines for systemic use, cough and cold preparations, and otological drugs.

use (diabetes: 12.1%; osteoporosis: 11.0%; psychotic disorders: 3.6%). Recognised GC indications were identified in 61.1% of long-term users. Among these potential indications, obstructive pulmonary diseases (26.2%), rheumatic diseases (12.1%) and inflammatory bowel diseases (3.3%) were the most frequent, and nearly 32% of these individuals had a cancer (table 1).

Among all GC users, concurrent antibiotics (59.1%), respiratory/otological drugs (50.1%) or both (31.8%) were frequently reimbursed at the index date, suggesting that underlying ENT (ear, nose, throat) and upper respiratory tract infections were often present (table 1).

Therapeutic behaviour associated with prescription of GCs

Among GC initiators, 1469 (0.7%) individuals were considered at increased risk of GC-induced osteoporosis related to long-term treatment (≥6 reimbursements/year) and to age (≥70 years) or to a history of non-treated osteoporosis. Among them, 61.5% had at least one measure aiming at preventing/monitoring osteoporosis over the year following treatment initiation: DXA was performed in 189 (12.9%) individuals and 891 (60.6%) individuals were reimbursed at least one drug for osteoporosis management. Nearly 55% of at-risk individuals received calcium and/or vitamin D, 27.4% a bisphosphonate and 5.0% another drug for osteoporosis prevention (table 2).

Over the year following treatment initiation, 10.8% of GC initiators had at least one concurrent reimbursement of oral GC and PPI without known concurrent NSAID or aspirin use; this concerned nearly half (49.8%) of long-term users versus 7.1% of short-term users. Concurrent reimbursement of oral GCs
Table 3 Measures for kalaemia and gastric protection associated with the prescription of oral GC therapy over the year following treatment start (figures are percentages)

<table>
<thead>
<tr>
<th></th>
<th>All GC initiators n=206759</th>
<th>Short-term users* n=139703</th>
<th>Mid-term users* n=63267</th>
<th>Long-term users* n=3789</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one concurrent reimbursement of GC and potassium supplements</td>
<td>1.3</td>
<td>0.5</td>
<td>1.8</td>
<td>23.7</td>
</tr>
<tr>
<td>Without any serum potassium level measurement during the preceding 2-week period</td>
<td>0.8</td>
<td>0.4</td>
<td>1.3</td>
<td>8.8</td>
</tr>
<tr>
<td>At least one concurrent reimbursement of GC and PPI without concurrent NSAID or aspirin use</td>
<td>10.8</td>
<td>7.1</td>
<td>16.7</td>
<td>49.8</td>
</tr>
</tbody>
</table>

*Short-term users: one reimbursement/year; mid-term users: 2–5 reimbursements/year; long-term users: ≥6 reimbursements.

GC, glucocorticoids; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor.


This population-based study provides a representative description of oral GC use in adults and its trends over the past 7 years in France. The annual prevalence of GC use in the general population, which was already high in 2007, increased by 14%, that is, about 2% per year. In 2014, 17% of the French adult population had at least one reimbursement of an oral GC. The overwhelming majority (68%) of new GC use was short-term (unique reimbursement) and apparently related to ENT and upper respiratory tract infections. Overall, 1.8% of GC initiators were considered as chronic users. Of note, comorbidities likely to be worsened by GC use (diabetes, psychotic disorders, osteoporosis) were found at treatment initiation among nearly one-quarter of chronic users. Therapeutic measures for the prevention of GC-induced osteoporosis appeared to be insufficiently prescribed among individuals judged at increased risk. Conversely, the concurrent prescription of PPIs and potassium supplementation was found to be frequent, in particular in chronic users, although the toxicity of GCs for the upper gastrointestinal tract and the risk of hypokalaemia are questionable or, at least, debated.

Strengths and weaknesses of study

The major strength of the study stands in the use of the EGB database, fully representative of the whole French population, which ensures the generalisability of the results to a national level. This use however implies some limitations inherent to almost all studies conducted on reimbursement claims databases. First, the database does not provide direct information about medical indication for each reimbursement, so we used data from diagnoses related to hospital stays or chronic diseases and concurrent drugs as proxies of potential GC indications. Second, given that the database does not provide the prescribed duration of treatments, this was defined according to the number of reimbursements per year. If a unique dispensing appears as an indisputable indicator of short-term use, we postulated that individuals with at least six reimbursements per year were chronic users even if renewals were not consecutive, which can be discussed.

Strengths and weaknesses in relation to other studies

The use of oral GCs in the general population has received little attention until now. Contrary to the present study, none of the previous studies were truly population-based.

DISCUSSION

Statement of principal findings

and potassium supplementation concerned 23.7% of long-term users, of whom 37.3% never had any serum potassium assay during the 2 weeks preceding the prescription. Conversely, concurrent use of oral GCs and potassium supplementation was infrequent among individuals who had <6 reimbursements of GCs over the year following treatment initiation (<2%) (table 3).
representative of the general source population, and the results from studies conducted on the UK medical databases seem to be the most comparable with ours. However, direct comparisons are hampered by methodological differences as those studies focused on long-term users. They found a prevalence estimate of about 1% at any moment, a 34% increase in their use being reported between 1989 and 2008. Our results regarding long-term users (who represented 98% of the cohort) are of concern. Moreover, short-term and mid-term users is of concern. Likewise, there is scarce evidence on the prevalence of psychotic disorders at oral GC initiation found in contraindication for GC therapy and the 3.6% prevalence of psychotic disorders at oral GC initiation found in long-term users was older, a high prevalence of diabetes monitoring in long-term GC users is very insufficient. A recent study that patients newly diagnosed with rheumatoid arthritis or inflammatory bowel diseases are less likely to receive long-term oral GC prescriptions today.

Possible explanations and implications for clinicians and policymakers

As mentioned above, 68% of GC initiators received a unique GC reimbursement, most of them being aged less than 50 years. Concurrent use of antibiotics and drugs for respiratory/otological disorders was frequently found at treatment initiation in these individuals, suggesting the presence of underlying ENT or upper respiratory tract infections. Oral GCs are relatively safe for short-term therapy. On the other hand, infections, neuropsychiatric disorders and worsening of pre-existent diabetes are known complications of GC therapy, even in those exposed only for a few days or weeks. The frequent pattern of use found in this study questions the rationale of prescribing oral GCs in adults. For example, first-line therapy for adult chronic sinusitis consists of daily saline irrigation with topical GC therapy. In this indication, a short course of systemic GC (1–3 weeks) should be considered only in the event of persistent symptoms or acute exacerbation, especially in patients with nasal polyps.

Also worrying was the high prevalence found for comorbidities predisposing to adverse reactions with oral GCs at treatment initiation in long-term users (25%). As long-term users were older, a high prevalence of diabetes was expected. Nevertheless, this frequent comorbidity requires attention given the available data showing that diabetes monitoring in long-term GC users is very insufficient. Also, adverse psychiatric reactions with GCs are also well known. Uncontrolled psychotic disorders are a contraindication for GC therapy and the 3.6% prevalence of psychotic disorders at oral GC initiation found in long-term users is of concern. Moreover, short-term and mid-term users (who represented 98% of the cohort) are also at risk, as neuropsychiatric symptoms could emerge within a few days or weeks of starting the treatment.

Another key result is the apparently inappropriate prescribing of therapeutic measures associated with GC therapy. The latter is a recognised cause of osteoporosis and osteoporosis management, and DXA measurement should be systematically undertaken in patients whose GC therapy is expected to exceed three consecutive months, especially those at high risk for fractures, including patients aged 70 years and over. In this study, the use of any drug for osteoporosis management was recorded for fewer than two-thirds of patients at increased risk; in particular only 27% were prescribed a bisphosphonate. DXA measurement was performed in 13%. This is consistent with previous reports that drugs for osteoporosis management and DXA measurement are used in only a minority of patients exposed to long-term GC therapy. Conversely, half of the long-term GC users had concurrent reimbursement of PPIs, apparently without any NSAID or aspirin use, although no consensus recommendation exists regarding the need for such gastric protection. Except in the event of concomitant NSAID use in elderly people, PPIs are advised only if patients have risk factors for peptic ulcer. Some practitioners prescribe potassium supplementation while others do not. The present findings suggest that this is infrequent in France except in long-term users (24%). The latter were more likely to be adequately monitored than short-term and mid-term users, two-thirds having kalaemia monitoring at least once, which is in line with a previous report.

Unanswered questions and future research

In conclusion, oral GC use is very widespread among adults in France and its prevalence steadily increased over the 2007–2014 period, the overwhelming majority of this being short-term. This could partly be due to an increase in the number of unjustified prescriptions that would exceed the number of those performed in situations where the benefit/risk ratio is recognised favourable. This hypothesis needs to be confirmed by further research and the impact of this extensive use in the population should be estimated. Moreover, our findings plead for the development of interventions designed to improve the monitoring of chronic users with regard to the frequent comorbidities at risk and inappropriate prescribing of preventive therapeutic measures.

Contributors ABL, AP, LF, BB, PN conceptualised and designed the work. EP collected the data and carried out the analysis. ABL, AP, LF, BB, PN interpreted the data. ABL wrote the first draft. All the authors critically revised and approved the final manuscript.

Funding The present study is part of the Drugs Systematized Assessment in real-life Environment (DRUGS-SAFE) research programme funded by the French Medicines Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM; grants received for the year 2016: 950,000 euros). This programme aims at providing an integrated system allowing the concomitant monitoring of drug use and control of comorbidities.
use and safety in France. The potential impact of drugs, frailty of populations and seriousness of risks drive the research programme. This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES